BioAge Labs, Inc. (NASDAQ: BIOA) has announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. This is expected to result in gross proceeds of approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioAge. The offering is expected to close on or about January 23, 2026.
Furthermore, BioAge has granted the underwriters a 30-day option to purchase up to an additional 884,615 shares of common stock in connection with the offering. The company intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and marketable securities, to fund research, clinical and process development and manufacturing of its product candidates, including BGE-102, and further development of its NLRP3 and APJ programs, as well as for working capital, capital expenditures, reduction of indebtedness, and other general corporate purposes.
It's worth noting that the shares are being offered by BioAge pursuant to a registration statement on Form S-3 (No. 333-290688) that became effective on November 25, 2025. The company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases. Additionally, BioAge is developing long-acting injectable and oral small molecule APJ agonists for obesity, with additional preclinical programs addressing key pathways involved in metabolic aging leveraging insights from the company’s proprietary discovery platform built on human longevity data. As a result of these announcements, the company's shares have moved -6.28% on the market, and are now trading at a price of $20.16. For the full picture, make sure to review BioAge Labs's 8-K report.
